Grant: Project Grant

Glycosaminoglycans are sugar chains attached to proteins. Chondroitin sulfate is a glycosaminoglycan that is distinctly modified in human cancers, including prostate cancer. In prostate cancer, chondroitin sulfate modifications are increased in tumors with inhibition or defects in the androgen receptor signaling pathway, commonly associated with resistant and advanced disease states. We have developed antibodies that are able to target cancer-associated chondroitin sulfate in solid tumors. These antibodies can be formulated as antibody-drug conjugates that are able to deliver cytotoxic payloads to the tumor environment as targeted therapies. In this project we attempt to qualify our first-in-class antibody-drug conjugates as a therapeutic option for advanced prostate cancers with androgen receptor pathway inhibition or defects.